Welcome to our dedicated page for Stepan SEC filings (Ticker: SCL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Stepan Company (NYSE: SCL) SEC filings page on Stock Titan brings together the company’s regulatory disclosures from the U.S. Securities and Exchange Commission, with AI-powered tools to help interpret the details. As a public issuer in the specialty and intermediate chemicals space, Stepan files annual reports on Form 10-K, quarterly reports on Form 10-Q and current reports on Form 8-K that describe its surfactants, polymers and specialty products businesses, financial results and governance matters.
In Stepan’s 10-K and 10-Q filings, readers can review segment information for surfactants, polymers and specialty products, along with discussions of sales volumes, selling prices, raw material cost pass-through, product mix and operating income. These reports also cover topics such as the company’s global manufacturing footprint in North and South America, Europe and Asia, and its role as a leading merchant producer of surfactants and supplier of polyurethane polyols for thermal insulation and CASE markets.
Form 8-K current reports provide updates on specific events, including quarterly earnings releases, dividend declarations, executive appointments or departures, board changes and adoption of plans such as the Key Executive Severance Benefit Plan. These filings give timely insight into Stepan’s capital allocation, leadership structure and key corporate actions.
Stock Titan enhances access to Stepan’s filings with AI-generated summaries that highlight the most important points in lengthy documents, helping users quickly understand complex financial and legal language. Real-time updates from EDGAR ensure that new Stepan filings appear promptly, while dedicated views for insider transaction reports (Form 4), proxy statements (Schedule 14A) and other forms allow deeper analysis of executive compensation, ownership changes and governance practices. This page serves as a focused resource for anyone researching SCL through its official SEC record.
Stepan Co vice president Robin Joseph Weitkamp received new equity awards as part of compensation. On April 13, 2026, he was granted 2,859 restricted stock units, each representing a contingent right to one share of Stepan common stock, vesting ratably over three years.
He also received 4,030 stock appreciation rights on Stepan common stock at an exercise price of $52.46 per share, exercisable beginning April 13, 2027 and expiring April 13, 2036. In addition, he was granted 1,429 performance shares, each a contingent right to one share that vests only if Stepan certifies that performance goals are achieved for the period ending December 31, 2028. These awards are grants, not open‑market purchases or sales.
Stepan Company VP and GM Surfactants NA Afonso Adriano Jose Galimberti received new equity-based awards as part of his compensation. On April 13, 2026, he was granted 1,310 performance shares, 2,621 restricted stock units, and 3,694 stock appreciation rights with a $52.46 exercise price. The performance shares vest if Stepan meets performance goals for the period ending December 31, 2028. The restricted stock units vest ratably over three years beginning on the grant date.
STEPAN CO executive Afonso Adriano Jose Galimberti, VP and GM Surfactants NA, filed an initial ownership report showing equity awards and share holdings. He holds stock options and stock appreciation rights over several thousand shares of common stock at exercise prices between $50.06 and $123.73, plus restricted stock units, performance shares, and direct and indirect common stock, including shares held through an ESOP II trust.
Stepan Company executive Robin Joseph Weitkamp, VP and GM Surfactants-INT, filed an initial ownership report showing various equity-based awards. The filing lists restricted stock units, stock appreciation rights and performance shares that each represent contingent rights to receive Stepan common stock, subject to time-based vesting and performance goals. It also notes an indirect holding of 96.9 shares of common stock through an ESOP II Trust.
Stepan Co ownership filing: The Vanguard Group filed Amendment No. 12 to Schedule 13G/A reporting that, after an internal realignment effective January 12, 2026, Vanguard and its disaggregated subsidiaries hold 0 shares of Stepan Co common stock, representing 0% of the class. The filing states Vanguard no longer is deemed to beneficially own securities held by those subsidiaries and confirms the reporting group’s voting and dispositive powers are all 0. The form is signed by the Head of Global Fund Administration on 03/27/2026.
Stepan Company has issued its 2026 proxy for the annual meeting on April 28, 2026 at its Northbrook, Illinois headquarters. Stockholders of record at the close of business on March 2, 2026, when 22,690,379 common shares were outstanding, are entitled to vote.
The agenda includes electing three directors (Joaquin Delgado, Corning F. Painter and F. Quinn Stepan, Jr.) to terms expiring in 2029, an advisory vote on executive compensation, and ratification of Deloitte & Touche LLP as independent auditor for 2026.
The board is majority independent, uses a separated Chair/CEO structure, and maintains four fully independent committees. BlackRock and The Vanguard Group beneficially own 14.1% and 11.3% of common stock, respectively, while directors and executives as a group hold 6.6%.
Compensation follows a pay-for-performance philosophy, with base salary less than half of target pay and significant short- and long-term incentives tied to earnings, EBITDA, free cash flow and safety. For 2025, corporate performance produced a 24.5% payout on company-wide metrics and annual bonuses of 15–25% of salary for most NEOs.
The proxy details substantial equity-based long-term incentives, robust stock ownership requirements, an updated clawback policy, an insider trading policy that restricts hedging and short sales, and a new key executive severance plan adopted in November 2025.
Stepan Company executive Richard Finn reported mixed equity transactions tied to restricted stock units (RSUs). On March 3 and 4, 2026, RSUs covering 1,253 and 429 units were settled into an equal number of Stepan common shares per award terms.
To cover tax liabilities on these vestings, Finn disposed of 434 and 149 common shares through tax-withholding transactions at prices of $48.985 and $49.615 per share. He continues to hold additional shares both directly and indirectly through family members and various trusts, as reflected in updated ownership balances.
Stepan Company President & CEO Luis Rojo reported equity award activity involving restricted stock units (RSUs) and common stock on March 3–4, 2026. RSUs were converted into common shares, and a portion of those shares was withheld to cover tax obligations.
On March 3, Rojo exercised 4,455 RSUs into the same number of Stepan common shares at a reference price of $48.985, then delivered 1,306 shares to satisfy tax liability. On March 4, he exercised another 857 RSUs at $49.615, with 252 shares withheld for taxes.
After these transactions, Rojo directly owned 19,451.666 shares of Stepan common stock and held 858 RSUs, with an additional 511.83 shares held indirectly through the ESOP II Trust.
Stepan Company executive Robert Joseph Haire reported equity award activity involving restricted stock units and common stock. On March 3 and 4, 2026, RSUs covering 2,241 shares were converted into Stepan common stock, consistent with the award terms that settle each RSU in one share.
To cover associated tax liabilities on these RSU vestings, Haire disposed of 658 common shares through share withholding transactions coded “F,” rather than open-market sales. After these transactions, he held 4,121.765 common shares directly and an additional 90.269 shares indirectly through the ESOP II Trust.